Monopar Therapeutics Inc’s filing revealed that its Chief Operating Officer Cittadine Andrew acquired Company’s shares for reported $15254.0 on Jun 20 ’24. In the deal valued at $0.74 per share,20,508 shares were bought. As a result of this transaction, Cittadine Andrew now holds 186,132 shares worth roughly $87482.04.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Cittadine Andrew bought 12,000 shares, generating $10,320 in total proceeds. Upon buying the shares at $0.86, the Chief Operating Officer now owns 165,624 shares.
Before that, Cittadine Andrew bought 12,000 shares. Monopar Therapeutics Inc shares valued at $10,799 were divested by the Chief Operating Officer at a price of $0.90 per share. As a result of the transaction, Cittadine Andrew now holds 153,624 shares, worth roughly $72203.28.
ROTH Capital initiated its Monopar Therapeutics Inc [MNPR] rating to a Buy in a research note published on January 28, 2021; the price target was $49.
Price Performance Review of MNPR
On Monday, Monopar Therapeutics Inc [NASDAQ:MNPR] saw its stock jump 6.56% to $0.47. Over the last five days, the stock has lost -22.79%. Monopar Therapeutics Inc shares have risen nearly 38.45% since the year began. Nevertheless, the stocks have fallen -37.12% over the past one year. While a 52-week high of $1.73 was reached on 02/23/24, a 52-week low of $0.27 was recorded on 02/07/24. SMA at 50 days reached $0.7205, while 200 days put it at $0.5886.
Levels Of Support And Resistance For MNPR Stock
The 24-hour chart illustrates a support level at 0.3745, which if violated will result in even more drops to 0.2781. On the upside, there is a resistance level at 0.5367. A further resistance level may holdings at 0.6025. The Relative Strength Index (RSI) on the 14-day chart is 28.51, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1392, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.06%. Stochastics%K at 19.89% indicates the stock is a buying.
How much short interest is there in Monopar Therapeutics Inc?
A steep rise in short interest was recorded in Monopar Therapeutics Inc stocks on
